| PD-1–and CTLA-4–based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses VD Fedorov, M Themeli, M Sadelain Science translational medicine 5 (215), 215ra172-215ra172, 2013 | 844 | 2013 |
| Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy M Themeli, CC Kloss, G Ciriello, VD Fedorov, F Perna, M Gonen, ... Nature biotechnology 31 (10), 928-933, 2013 | 522 | 2013 |
| A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization E Drent, M Themeli, R Poels, R de Jong-Korlaar, H Yuan, J de Bruijn, ... Molecular therapy 25 (8), 1946-1958, 2017 | 270 | 2017 |
| New cell sources for T cell engineering and adoptive immunotherapy M Themeli, I Rivière, M Sadelain Cell stem cell 16 (4), 357-366, 2015 | 216 | 2015 |
| Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma E Drent, RWJ Groen, WA Noort, M Themeli, JJL van Bueren, PWHI Parren, ... haematologica 101 (5), 616, 2016 | 194 | 2016 |
| Combined CD28 and 4-1BB costimulation potentiates affinity-tuned chimeric antigen receptor–engineered T cells E Drent, R Poels, R Ruiter, NWCJ van de Donk, S Zweegman, H Yuan, ... Clinical Cancer Research 25 (13), 4014-4025, 2019 | 158 | 2019 |
| CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia J Naik, M Themeli, R de Jong-Korlaar, RWJ Ruiter, PJ Poddighe, H Yuan, ... Haematologica 104 (3), e100, 2019 | 120 | 2019 |
| Induced pluripotent stem cell (iPSC)–derived lymphocytes for adoptive cell immunotherapy: recent advances and challenges A Nianias, M Themeli Current hematologic malignancy reports 14, 261-268, 2019 | 92 | 2019 |
| Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design E Drent, R Poels, MJ Mulders, NWCJ van de Donk, M Themeli, ... PloS one 13 (5), e0197349, 2018 | 79 | 2018 |
| Effective generation of tumor-targeted t-cells derived from pluripotent stem cells M Themeli, M Sadelain, CC Kloss | 74 | 2014 |
| Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence A Katsarou, M Sjöstrand, J Naik, J Mansilla-Soto, D Kefala, G Kladis, ... Science translational medicine 13 (623), eabh1962, 2021 | 68 | 2021 |
| Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma NWCJ van de Donk, M Themeli, SZ Usmani Blood cancer discovery 2 (4), 302-318, 2021 | 53 | 2021 |
| CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience KA Frerichs, NA Nagy, PL Lindenbergh, P Bosman, J Marin Soto, ... Expert Review of Clinical Immunology 14 (3), 197-206, 2018 | 52 | 2018 |
| Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells SJC van der Stegen, PL Lindenbergh, RM Petrovic, H Xie, MP Diop, ... Nature biomedical engineering 6 (11), 1284-1297, 2022 | 47 | 2022 |
| Preclinical evaluation of invariant natural killer T cells modified with CD38 or BCMA chimeric antigen receptors for multiple myeloma R Poels, E Drent, R Lameris, A Katsarou, M Themeli, HJ van der Vliet, ... International journal of molecular sciences 22 (3), 1096, 2021 | 44 | 2021 |
| Alloreactive microenvironment after human hematopoietic cell transplantation induces genomic alterations in epithelium through an ROS-mediated mechanism: in vivo and in vitro … M Themeli, L Petrikkos, M Waterhouse, H Bertz, E Lagadinou, N Zoumbos, ... Leukemia 24 (3), 536-543, 2010 | 38 | 2010 |
| Bone marrow mesenchymal stromal cells can render multiple myeloma cells resistant to cytotoxic machinery of CAR T cells through inhibition of apoptosis LC Holthof, JJ van der Schans, A Katsarou, R Poels, AT Gelderloos, ... Clinical Cancer Research 27 (13), 3793-3803, 2021 | 37 | 2021 |
| Time to evolve: predicting engineered T cell-associated toxicity with next-generation models E Donnadieu, M Luu, M Alb, B Anliker, S Arcangeli, C Bonini, ... Journal for immunotherapy of cancer 10 (5), 2022 | 34 | 2022 |
| The tumor vasculature an attractive CAR T cell target in solid tumors P Akbari, EJM Huijbers, M Themeli, AW Griffioen, JR van Beijnum Angiogenesis 22, 473-475, 2019 | 32 | 2019 |
| Escape mutations, ganciclovir resistance, and teratoma formation in human iPSCs expressing an HSVtk suicide gene AG Kotini, E De Stanchina, M Themeli, M Sadelain, EP Papapetrou Molecular Therapy-Nucleic Acids 5, 2016 | 31 | 2016 |
